Inactivation of three emerging viruses – severe acute respiratory syndrome coronavirus, Crimean-Congo haemorrhagic fever virus and Nipah virus – in platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light (2020)

Peer-Reviewed Study · Eickmann M; Gravemann U; Handke W; Tolksdorf F; Reichenberg S; Müller TH; Seltsam A · January 12, 2020

Eickmann M et al., 2020-01-12: Spike study showing methylene blue plus visible light inactivates SARS-CoV, Crimean-Congo haemorrhagic fever virus and Nipah virus in plasma to the detection limit at a quarter of the full light dose (120 J/cm2).

treatment with MB and a fourth of the full light dose (120 J/cm2 ) decreased that of SARS-CoV (≥3·1 log), CCHFV (≥3·2 log) and NiV (≥2·7 log) to the LOD in plasma.

Abstract

Eickmann M et al., 2020-01-12: Spike study showing methylene blue plus visible light inactivates SARS-CoV, Crimean-Congo haemorrhagic fever virus and Nipah virus in plasma to the detection limit at a quarter of the full light dose (120 J/cm2). Study type: in vitro virus-spiking study in plasma and platelet concentrates; no human subjects. Country: Germany (German Red Cross Blood Service, Philipps University Marburg). Funding: German Red Cross Blood Services and Macopharma S.A.S. (declared). Conflicts (declared verbatim in the record): 'FT and SR are employees of Macopharma, manufacturer and distributor of the THERAFLEX pathogen inactivation (PI) system. UG, WH, THM and AS received project grants from the German Red Cross Blood Services and Macopharma for the development of the UVC-based PI technology for platelets.' This is the direct manufacturer-funded evidence base for the plasma system. Study type: lab.